NDRG2 expression decreases with tumor stages and regulates TCF/ β-catenin signaling in human colon carcinoma

Carcinogenesis

Volumn 30, Issue 4, 2009, Pages 598-605

  Kim, Young Jun ^a   Yoon, Sun Y ^b   Kim, Jong Tae ^a   Song, Eun Y ^a   Lee, Hee G ^a   Son, Hyun J ^c   Kim, Soo Y ^c   Cho, Daeho ^b   Choi, Inpyo ^a   Kim, Joo Heon ^c   Kim, Jae W ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Eulji University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; N MYC DOWNSTREAM REGULATED PROTEIN 2; T CELL FACTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE DELETION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; BETA CATENIN; BLOTTING, WESTERN; CELL MEMBRANE; COLON; COLORECTAL NEOPLASMS; CYTOSOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LUCIFERASES; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 64349090438     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp047     Document Type: Article

References (39)

1. Zhang,J. et al. (2006) The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J. Biol. Chem., 281 39159-39168.
2. Kovacevic,Z. et al. (2006) The metastasis suppressor, Ndrg-1: A new ally in the fight against cancer. Carcinogenesis, 27, 2355-2366.
3. Liu,N. et al. (2007) Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem. Biophys. Res. Commun., 358 164-169.
4. Lusis,E.A. et al. (2005) Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res., 65, 7121-7126.
5. Hu,X.L. et al. (2004) NDRG2 expression and mutation in human liver and pancreatic cancers. World J. Gastroenterol., 10, 3518-3521.
6. Deng,Y. et al. (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int. J. Cancer, 106 342-347.
7. Takahashi,K. et al. (2005) Ndrg2 promotes neurite outgrowth of NGF-differentiated PC12 cells. Neurosci. Lett., 388, 157-162.
8. Nichols,N.R. et al. (2005) Glucocorticoid regulation of glial responses during hippocampal neurodegeneration and regeneration. Brain Res. Brain Res. Rev., 48, 287-301.
9. Mitchelmore,C. et al. (2004) NDRG2: A novel Alzheimer's disease associated protein. Neurobiol. Dis., 16, 48-58.
10. Choi,S.C. et al. (2003) Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells. FEBS Lett., 553, 413-418.
11. Burchfield,J.G. et al. (2004) Akt mediates insulin-stimulated phosphorylation of Ndrg2: Evidence for cross-talk with protein kinase C theta. J. Biol. Chem., 279, 18623-18632.
12. Boulkroun,S. et al. (2002) Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene. J. Biol. Chem., 277, 31506-31515.
13. Murray,J.T. et al. (2004) Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem. J., 384, 477-488.
14. Woodgett,J.R. (1994) Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin. Cancer Biol., 5, 269-275.
15. Cook,D. et al. (1996) Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J., 15, 4526-4536.
16. Harwood,A.J. (2001) Regulation of GSK-3: A cellular multiprocessor. Cell, 105, 821-824.
17. Peifer,M. et al. (2000) Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science, 287, 1606-1609.
18. Taipale,J. et al. (2001) The Hedgehog and Wnt signalling pathways in cancer. Nature, 411, 349-354.
19. Bienz,M. et al. (2000) Linking colorectal cancer to Wnt signaling. Cell, 103, 311-320.
20. Moon,R.T. et al. (2002) The promise and perils of Wnt signaling through beta-catenin. Science, 296, 1644-1646.
21. Henderson,B.R. et al. (2002) The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep., 3, 834-839.
22. Shelton,D.N. et al. (2006) Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development. Cancer Res., 66, 7571-7577.
23. Liu,J.J. et al. (2006) Repression of HIP/RPL29 expression induces differentiation in colon cancer cells. J. Cell. Physiol., 207 287-292.
24. Chakrabarty,S. et al. (2003) Extracellular calcium and calcium sensing receptor function in human colon carcinomas: Promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. Cancer Res., 63, 67-71.
25. Mariadason,J.M. et al. (2001) Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res., 61, 3465-3471.
26. Rockman,S.P. et al. (2001) Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma. J. Biol. Chem., 276, 45113-45119.
27. Kim,Y.J. et al. (2009) NDRG2 suppresses cell proliferation through downregulation of AP-1 activity in human colon carcinoma cells. Int. J. Cancer, 124, 7-15.
28. Cohen,P. et al. (2001) The renaissance of GSK3. Nat. Rev. Mol. Cell Biol., 2, 769-776.
29. Liu,C. et al. (2002) Control of beta-catenin phosphorylation/ degradation by a dual-kinase mechanism. Cell, 108, 837-847.
30. Salic,A. et al. (2000) Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts. Mol. Cell, 5, 523-532.
31. Behrens,J. et al. (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science, 280, 596-599.
32. Tetsu,O. et al. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 398, 422-426.
33. He,T.C. et al. (1998) Identification of c-MYC as a target of the APC pathway. Science, 281, 1509-1512.
34. Lorentzen,A. et al. (2007) Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer, 7 192.
35. Lee,D.C. et al. (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res., 68, 4210-4220.
36. Guan,R.J. et al. (2000) Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res., 60, 749-755.
37. Schakman,O. et al. (2008) Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology, 149, 3900-3908.
38. Gu,D. et al. (2007) The effect of pleiotrophin signaling on adipogenesis. FEBS Lett., 581, 382-388.
39. Liang,J. et al. (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle, 2, 339-345.